Gamma Delta Hepatosplenic T-Cell Lymphoma
1 clinical trials · Condition
◉ Watch Gamma Delta Hepatosplenic T-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas (NCT01445535) | National Cancer Institute (NCI) | 2009-01-13 |
Track Gamma Delta Hepatosplenic T-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.